Popular Trials
Antioxidant
Antioxidant Therapy with N-acetylcysteine for Neurofibromatosis Type 1
This trial tests N-Acetyl Cysteine (NAC), a common supplement, to see if it can help children with neurofibromatosis type 1 (NF1) who have cognitive, behavioral, and motor issues. NAC works by reducing harmful substances in the brain, potentially improving behavior and motor skills. NAC is a precursor to glutathione (GSH) and has been studied for its neuroprotective and cognitive benefits in various conditions.
Behavioural Intervention
Educational Letters for Neurofibromatosis
This trial aims to compare two educational interventions for individuals with Neurofibromatosis 1 (NF1) to see which one helps more in getting proper health screenings for NF1 patients in regular doctor
MEK Inhibitor
Trametinib for Cancer With NF1 Genetic Changes
This trial tests trametinib, an oral medication, in patients with advanced cancers having an NF1 mutation. Trametinib works by blocking proteins that help cancer cells grow, aiming to stop or slow down the cancer. Trametinib is approved for treating certain types of advanced cancers.
MEK Inhibitor
MEK Inhibitor for Neurofibromatosis
This trial tests mirdametinib, a medication taken by mouth, for patients with NF1-related tumors that can't be surgically removed. The drug works by blocking specific proteins to stop or shrink the tumors. Mirdametinib has shown significant and lasting decreases in pain and partial responses in NF1-related plexiform neurofibromas.
Diagnostic Test
Whole Body MRI for Neurofibromatosis
This study is being conducted to determine if Whole Body MRI (WBMRI) can be used to identify Atypical Neurofibromas (ANF) in Neurofibromatosis Type 1 (NF1) patients with high tumor burden. Each enrolled participant will have two (2) WBMRIs without sedation during the study period. Eligible participants must be Male or Female between the ages of 8-30 with diagnosed NF1; with one or more PN greater than 3cm in diameter and willing to comply with study procedures.
Popular Filters
Trials for NF Patients
Dietary Supplement
Nutraceuticals for Neurofibromatosis
This trial involves taking curcumin and a special type of olive oil twice a day to help reduce inflammation and oxidative stress. It targets individuals who can tolerate this treatment for an extended period. Curcumin is a natural polyphenol known for its antioxidant and anti-inflammatory properties, and it has been studied in various contexts including metabolic syndrome, diabetes, and exercise-induced oxidative stress.
Behavioural Intervention
Acceptance and Commitment Therapy for Caregivers of Children with Genetic Syndromes
This trial will test whether Acceptance and Commitment Therapy (ACT) can help caregivers of children with a RASopathy better cope with parenting stress.
MEK1/2 inhibitor
FCN-159 for Neurofibromatosis
This trial is testing FCN-159, a new drug taken by mouth, for patients with advanced solid tumors and neurofibromatosis type 1. The drug works by blocking specific proteins that help cancer cells grow. This targeted approach aims to slow down or stop the progression of these diseases.
Kinase Inhibitor
Selumetinib for Plexiform Neurofibromas
This trial is testing a medication called selumetinib to see if it can help adults with a condition called NF1 who have tumors that cause symptoms and cannot be removed by surgery. The medication works by blocking signals that make the tumors grow.
Trials for Neurofibroma Patients
Dietary Supplement
Nutraceuticals for Neurofibromatosis
This trial involves taking curcumin and a special type of olive oil twice a day to help reduce inflammation and oxidative stress. It targets individuals who can tolerate this treatment for an extended period. Curcumin is a natural polyphenol known for its antioxidant and anti-inflammatory properties, and it has been studied in various contexts including metabolic syndrome, diabetes, and exercise-induced oxidative stress.
Behavioural Intervention
Acceptance and Commitment Therapy for Caregivers of Children with Genetic Syndromes
This trial will test whether Acceptance and Commitment Therapy (ACT) can help caregivers of children with a RASopathy better cope with parenting stress.
MEK1/2 inhibitor
FCN-159 for Neurofibromatosis
This trial is testing FCN-159, a new drug taken by mouth, for patients with advanced solid tumors and neurofibromatosis type 1. The drug works by blocking specific proteins that help cancer cells grow. This targeted approach aims to slow down or stop the progression of these diseases.
Kinase Inhibitor
Selumetinib for Plexiform Neurofibromas
This trial is testing a medication called selumetinib to see if it can help adults with a condition called NF1 who have tumors that cause symptoms and cannot be removed by surgery. The medication works by blocking signals that make the tumors grow.
Trials for NF1 Positive Patients
MEK1/2 inhibitor
FCN-159 for Neurofibromatosis
This trial is testing FCN-159, a new drug taken by mouth, for patients with advanced solid tumors and neurofibromatosis type 1. The drug works by blocking specific proteins that help cancer cells grow. This targeted approach aims to slow down or stop the progression of these diseases.
Kinase Inhibitor
Selumetinib for Plexiform Neurofibromas
This trial is testing a medication called selumetinib to see if it can help adults with a condition called NF1 who have tumors that cause symptoms and cannot be removed by surgery. The medication works by blocking signals that make the tumors grow.
CDK4/6 Inhibitor
Abemaciclib for Neurofibroma
This trial is testing a drug, abemaciclib, to see if it can help treat atypical neurofibromas, which are tumors that arise from nerves and can cause serious medical problems. The drug is taken orally, twice daily, in 28-day cycles.
Antioxidant
Antioxidant Therapy for Neurofibromatosis Type 1
This trial is testing a medication called NAC in children aged 8-16 with a condition called NF1. These children often have problems with movement and behavior, and there is no current treatment for these issues. NAC works by reducing harmful molecules in the brain, which may help improve these symptoms.
Trials With No Placebo
Dietary Supplement
Nutraceuticals for Neurofibromatosis
This trial involves taking curcumin and a special type of olive oil twice a day to help reduce inflammation and oxidative stress. It targets individuals who can tolerate this treatment for an extended period. Curcumin is a natural polyphenol known for its antioxidant and anti-inflammatory properties, and it has been studied in various contexts including metabolic syndrome, diabetes, and exercise-induced oxidative stress.
Behavioural Intervention
Acceptance and Commitment Therapy for Caregivers of Children with Genetic Syndromes
This trial will test whether Acceptance and Commitment Therapy (ACT) can help caregivers of children with a RASopathy better cope with parenting stress.
MEK1/2 inhibitor
FCN-159 for Neurofibromatosis
This trial is testing FCN-159, a new drug taken by mouth, for patients with advanced solid tumors and neurofibromatosis type 1. The drug works by blocking specific proteins that help cancer cells grow. This targeted approach aims to slow down or stop the progression of these diseases.
CDK4/6 Inhibitor
Abemaciclib for Neurofibroma
This trial is testing a drug, abemaciclib, to see if it can help treat atypical neurofibromas, which are tumors that arise from nerves and can cause serious medical problems. The drug is taken orally, twice daily, in 28-day cycles.
View More Related Trials
Frequently Asked Questions
Introduction to nf1
What are the top hospitals conducting nf1 research?
When it comes to clinical trials focused on the treatment and understanding of neurofibromatosis type 1 (NF1), several esteemed hospitals stand out for their significant contributions. At the forefront is the National Institutes of Health Clinical Center in Bethesda, where researchers are currently conducting six active NF1 trials, building upon a remarkable history of 20 previous studies dating back to their initial trial in 2005. In Cincinnati, the Children's Hospital Medical Center has also made substantial strides with five ongoing NF1 trials and an impressive record of 21 completed studies since embarking on their first trial in 2005.
Meanwhile, in Philadelphia, another prominent institution dedicated to pediatric healthcare, the Children's Hospital of Philadelphia, is actively involved in five NF1 trials while having conducted a commendable total of 19 previous investigations since initiating their inaugural trial in 2001. On the West Coast, children diagnosed with NF1 can find solace at Children's Hospital Los Angeles. With four ongoing clinical trials focused on this condition and a track record encompassing thirteen prior studies starting from their first recorded NF1 trial in 2009.
Furthermore contributing towards research endeavors related to NF1 is Children's National Medical Center located within Washington DC where they have four active nf-2 tests while carrying out twenty earlier researched ones after initiating its pioneering investigation into such cases way back until year two thousand two.
These leading hospitals exemplify dedication and innovation as they strive to advance our knowledge about neurofibromatosis type 1 through cutting-edge clinical trials. By joining forces and pushing boundaries within these medical centers across different regions , doctors hope not only to improve treatments but also provide patients affected by this rare genetic disorder with increased comfort along side offering them brighter future prospects ahead
Which are the best cities for nf1 clinical trials?
When it comes to nf1 clinical trials, several cities are at the forefront of research and development. Bethesda, Maryland leads with 13 active trials investigating treatments like Selumetinib and AZD6244. Philadelphia, Pennsylvania follows closely behind with 11 ongoing studies focused on innovative approaches such as Selumetinib granule formulation and Mirdametinib. Los Angeles, California, Chicago, Illinois, and Cincinnati, Ohio also contribute significantly to nf1 research through their respective active trials. These cities offer individuals affected by nf1 access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in treatment options.
Which are the top treatments for nf1 being explored in clinical trials?
Clinical trials are paving the way for advancements in treating nf1, with several promising treatments leading the charge. Selumetinib takes center stage with its involvement in four active trials and a total of 10 nf1 trials since its introduction in 2010. Joining the ranks is curcumin, high phenolic extra virgin olive oil (HP-EVOO), showing promise in one active trial and one all-time nf1 trial listed as recent as 2022. Additionally, ACT Intervention and FCN-159 demonstrate potential through their participation in one active trial each, contributing to the growing body of research aiming to combat nf1. These ongoing clinical investigations offer hope for improved therapeutic options for patients facing this challenging condition.
What are the most recent clinical trials for nf1?
Recent clinical trials for neurofibromatosis type 1 (NF1) hold promise in advancing treatment options for individuals affected by this condition. One notable trial involves the utilization of a flu and total body irradiation regimen, which has entered phase 2 and became available on May 11, 2023. Additionally, a phase 1 trial exploring the potential benefits of DPCP for NF1 patients was initiated on September 14, 2022. Another phase 1 trial investigated the effects of curcumin and high phenolic extra virgin olive oil as potential therapies for NF1; it became available on July 6, 2022. The development of selumetinib granule formulation is another significant breakthrough in the treatment landscape of NF1; it entered phases 1 and 2 on January21st ,2022 . Lastly,poly ICLC research reached phase two with availability starting from December15th ,202.
What nf1 clinical trials were recently completed?
Recently completed clinical trials in the field of neurofibromatosis type 1 (NF1) have made significant strides towards advancing treatment options for this genetic disorder. These trials address the specific challenges associated with NF1 and aim to improve patient outcomes. Researchers are making notable progress in understanding and targeting the mechanisms underlying NF1, bringing hope to individuals affected by this condition.